Topics

ChAdOx1 85A Aerosol Versus Intramuscular Vaccination in Healthy Adults (TB039)

2019-10-16 10:39:39 | BioPortfolio

Summary

This is a dose escalating and a paired-placebo design study to describe the safety and immunogenicity profile of candidate TB vaccine ChAdOx1 85A given by aerosol inhaled vaccination versus intramuscular (IM) vaccination in adult healthy volunteers.

It is postulated that the aerosol inhaled route is practical and feasible and has an acceptable safety profile, comparable to the systemic safety profile of the IM route of administration of ChAdOx1 85A in adult healthy volunteers, and that the aerosol inhaled route of administration will induce greater mucosal immunity and comparable systemic immunity when compared to the IM (systemic) route of administration in these volunteers.

Volunteers are followed on a regular basis for safety and immunogenicity, with blood analysis for biological safety tests and immune tests.

Description

Background:

Mycobacterium tuberculosis (M.tb) is a pathogen with worldwide preponderance which infects humans and causes tuberculosis (TB), a transmissible disease resulting in very high mortality and morbidity. A third of the world's population is latently infected with M.tb, and these people carry a 10% lifetime risk of developing active life-threatening disease. In 2015, there were 10.4 million new cases worldwide and 1.8 million people died of TB. Co-infection with human immunodeficiency virus (HIV) greatly increases risk of TB reactivation and death. Diagnosis is challenging and drug treatment can be prolonged, harmful, costly and complex. For these reasons an effective TB vaccine is a global public health priority.

The Bacille Calmette-Guérin (BCG) vaccine is the only licensed TB vaccine and it has been administered globally to several billion people over a 90 year period. Although it does not protect against pulmonary TB in endemic areas, it is effective in preventing disseminated TB disease including tuberculous meningitis in childhood. Recently, heterologous "prime-boost" vaccination strategies, in which two different candidate vaccines expressing antigens in common are given weeks or months apart, have generated strong and sustained cellular immune responses correlating with an M.tb protective effect in preclinical animal models. In such a "prime-boost" strategy, BCG would therefore be an ideal priming vaccine.

ChAdOx1 85A is a new adenoviral vaccine based on a vector that is a chimpanzee adenovirus isolate Y25 expressing the M.tb antigen 85A. Adenoviruses are attractive candidates for use as viral vectors and have been used as vaccine vectors for a number of conditions; however the use has been limited by the high level of anti-vector immunity present in humans in whom adenovirus is a ubiquitous infection. This has led to the consideration of simian adenoviruses, which are not known to cause pathology or illness in humans and to which the prevalence of anti-vector antibodies is low.

The route of M.tb infection is by inhalation of aerosolised infectious droplets containing tubercle bacilli, leading to the establishment of primary infection in the lung, which has a distinct mucosal immune system characterized by bronchus associated lymphoid tissue (BALT), which is well adapted to encounter and process such antigens. Immunising via the airway should therefore have the advantage, over other routes, of eliciting protective immune responses in the lung mucosa. There is data from preclinical animal models with virally vectored vaccines to suggest that immunising the respiratory mucosa may give superior protection against respiratory diseases. The inhaled route is a well-established route of drug delivery for humans and there are numerous perceived advantages of aerosol inhaled vaccination.

This trial will be the first to evaluate the safety and immunogenicity of candidate TB vaccine ChAdOx1 85A given by aerosol inhaled vaccination. Using a paired-placebo design, the trial will investigate aerosol vaccination compared to intramuscular vaccination, the latter for which initial safety data has already been collected and from which the dosing regimen for this trial has been chosen.

Objective:

The study aims to describe the safety and immunogenicity profile for ChAdOx1 85A given by aerosol inhaled vaccination versus intramuscular (IM) vaccination in adult healthy volunteers.

Methods:

Thirty-nine subjects will be enrolled into the trial: 29 BCG-vaccinated and 10 BCG-naïve.

Nine BCG-vaccinated healthy volunteers will receive the ChAdOx1 85A vaccine by aerosol inhaled vaccination at three different dose levels (3 volunteers per dose levels, Groups A-B-C). Based on the safety profile and immunogenicity results obtained in Groups A, B and C, the highest tolerated dose will be determined, and a decision made as to which dose to use for subsequent Groups.

The next 20 BCG-vaccinated subjects will be blinded and randomised in Groups D and E: volunteers randomised to the intervention group (D, inhaled aerosol) will receive a concurrent intramuscular saline injection, while volunteers in the control group (E, intramuscular) will receive a concurrent dose of inhaled saline. This design has the added benefit of allowing a distinction to be made between any adverse events attributable to the method (including nebuliser device) of vaccine delivery and those attributable to the inhaled investigational medicinal product itself.

In parallel to enrolment of Groups D and E, 10 BCG naïve subjects will be enrolled in Group F to receive the highest tolerated dose by aerosol inhaled vaccination.

After vaccination (day 0), volunteers will then follow a schedule of visits over the six months (day 1, day 7, day 14, day 28, day 84 and day 168), for safety and immunological follow-up via blood tests and physical examination. Moreover, at day 14, volunteers will undergo a bronchoscopy to check for signs of inflammation or other damage and to obtain a bronchoalveolar lavage sample and lymph node cytopunction.

Impact:

The overall investigational approach with ChAdOx1 85A trials is to develop an effective prime-boost vaccination strategy to prevent TB infection, with BCG as the priming vaccine.

Study Design

Conditions

Mycobacterium Tuberculosis, Protection Against

Intervention

ChadOx1 85A - aerosol, ChadOx1 85A - IM

Location

Centre hospitalier universitaire vaudois
Lausanne
Switzerland
1011

Status

Recruiting

Source

Centre Hospitalier Universitaire Vaudois

Results (where available)

View Results

Links

Published on BioPortfolio: 2019-10-16T10:39:39-0400

Clinical Trials [791 Associated Clinical Trials listed on BioPortfolio]

Safety and Immunogenicity of a Candidate ZIKV Vaccine (ZIKA001)

This is a FIH, open-label, dose escalation, phase I clinical trial to assess the safety and immunogenicity of the candidate ChAdOx1 Zika vaccine in healthy volunteers given as a standalone...

A Safety and Efficacy Study of ChAdOx1 LS2

The purpose of this study is to assess the safety, immunogenicity and efficacy of the candidate malaria vaccine ChAdOx1 LS2. Healthy adult volunteers will be recruited and vaccinated in O...

EMaBS TB Vaccine Study

The study will commence with a dose-escalation and age de-escalation study in healthy adults and adolescents in Uganda, focussing on ChAdOx1 85A, to provide safety data for ChAdOx1 85A in ...

MVA85A Aerosol vs Intramuscular Vaccination in Adults With Latent Mycobacterium Tuberculosis (M. tb) Infection

TB040 is a clinical trial to investigate and compare the effects of a candidate Tuberculosis (TB) vaccine, MVA85A, administered by the aerosol inhaled route and the intramuscular route in ...

Safety and Immunogenicity of a Candidate MERS-CoV Vaccine (MERS001)

This is a clinical trial in which healthy volunteers will be administered an experimental MERS vaccine. The vaccine ChAdOx1 MERS will be administered alone as a single administration.

PubMed Articles [3472 Associated PubMed Articles listed on BioPortfolio]

Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.

There is an urgent need for an effective tuberculosis (TB) vaccine. Heterologous prime-boost regimens induce potent cellular immunity. MVA85A is a candidate TB vaccine. This phase I clinical trial was...

Changes in transcript, metabolite and antibody reactivity during the early protective immune response in humans to Mycobacterium tuberculosis infection.

Strategies to prevent Mycobacterium tuberculosis (Mtb) infection are urgently required. This study aimed to identify correlates of protection against early Mtb infection.

Use of an outbred rat hepacivirus challenge model for design and evaluation of efficacy of different immunisation strategies for HCV.

The lack of immunocompetent small animal models for hepatitis C virus (HCV) has greatly hindered the development of effective vaccines. Using rodent hepacivirus (RHV), a homologue of HCV that shares m...

Myeloid HIF-1α regulates pulmonary inflammation during experimental Mycobacterium tuberculosis infection.

The transcription factor hypoxia inducible factor-1 alpha (HIF-1α) is as key regulator of the response and function of myeloid cells in hypoxic and inflammatory microenvironments. To define the role ...

Association between CLEC4E gene polymorphism of Mincle and pulmonary tuberculosis infection in a northern Chinese population.

Pulmonary tuberculosis caused by an intracellular pathogen, Mycobacterium tuberculosis continues to exist as a hazardous disease to human life globally. Genetic polymorphisms regulate resistance and s...

Medical and Biotech [MESH] Definitions

The dormant form of TUBERCULOSIS where the person shows no obvious symptoms and no sign of the causative agent (Mycobacterium tuberculosis) in the SPUTUM despite being positive for tuberculosis infection skin test.

Tuberculosis of the brain, spinal cord, or meninges (TUBERCULOSIS, MENINGEAL), most often caused by MYCOBACTERIUM TUBERCULOSIS and rarely by MYCOBACTERIUM BOVIS. The infection may be limited to the nervous system or coexist in other organs (e.g., TUBERCULOSIS, PULMONARY). The organism tends to seed the meninges causing a diffuse meningitis and leads to the formation of TUBERCULOMA, which may occur within the brain, spinal cord, or perimeningeal spaces. Tuberculous involvement of the vertebral column (TUBERCULOSIS, SPINAL) may result in nerve root or spinal cord compression. (From Adams et al., Principles of Neurology, 6th ed, pp717-20)

Infection of the LIVER with species of MYCOBACTERIUM, most often MYCOBACTERIUM TUBERCULOSIS. It is characterized by localized small tuberculous miliary lesions or tumor-like mass (TUBERCULOMA), and abnormalities in liver function tests.

Infection of the ENDOCRINE GLANDS with species of MYCOBACTERIUM, most often MYCOBACTERIUM TUBERCULOSIS.

Pathological conditions of the CARDIOVASCULAR SYSTEM caused by infection of MYCOBACTERIUM TUBERCULOSIS. Tuberculosis involvement may include the HEART; the BLOOD VESSELS; or the PERICARDIUM.

More From BioPortfolio on "ChAdOx1 85A Aerosol Versus Intramuscular Vaccination in Healthy Adults (TB039)"

Quick Search

Relevant Topics

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...

Vaccine
A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one ...


Searches Linking to this Trial